Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03962465
Title Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001)
Acronym ALL-001
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Virginia
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
University of Virginia Charlottesville Virginia 22908 United States Details
VCU Massey Cancer Center Richmond Virginia 23298 United States Details
University of Wisconsin Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field